The oncology portfolio
Bristol-Myers Squibb’s (BMY) oncology portfolio includes key products Empliciti, Opdivo, Sprycel, and Yervoy. The oncology portfolio contributes over 40% of Bristol-Myers Squibb’s total revenue.
The above chart compares key oncology products’ revenue over the last few quarters. Empliciti is the latest drug launched by Bristol-Myers Squibb for the treatment of multiple myeloma. Empliciti reported revenue of $60 million in 3Q17, 46% growth from 3Q16.
Opdivo is developed in alliance with Ono Pharmaceutical. Opdivo, one of the largest-selling drugs from Bristol-Myers Squibb’s portfolio, is approved for the treatment of various forms of cancer, including non-small cell lung cancer, squamous cell carcinoma, classical Hodgkin’s lymphoma, metastatic melanoma, renal cell carcinoma, hepatocellular carcinoma, and urothelial carcinoma. Opdivo reported revenue of $1.3 billion in 3Q17, 38% growth from 3Q16.
Sprycel, another key drug from Bristol-Myers Squibb’s oncology portfolio, is approved for the treatment of Philadelphia chromosome–positive chronic myeloid leukemia. Sprycel reported revenue of $509 million in 3Q17, 8% growth from 3Q16.
Yervoy is approved for the treatment of melanoma. Yervoy reported revenue of $323 million in 3Q17, 13% growth from 3Q16. Notably, the PowerShares Dynamic Pharmaceuticals ETF (PJP) has a 5.0% exposure to Bristol-Myers Squibb (BMY), a 5.1% exposure to Eli Lilly (LLY), a 5.0% exposure to Pfizer (PFE), and a 5.0% exposure to AbbVie (ABBV).